influenza
persist
threat
human
health
continu
requir
updat
antiinfluenza
strategi
initi
observ
differ
endoplasm
reticulum
er
respons
host
season
highli
pathogen
avian
influenza
hpai
infect
identifi
altern
antivir
role
tauroursodeoxychol
acid
tudca
clinic
avail
er
stress
inhibitor
vitro
vivo
rather
modul
er
stress
host
cell
tudca
abolish
proton
conduct
viral
disrupt
oligomer
state
induc
ineffici
viral
infect
also
show
penetr
cell
whose
intracellular
uptak
depend
proton
channel
activ
effect
observ
tudca
inhibitor
amantadin
identif
applic
tudca
inhibitor
proton
channel
expand
understand
iav
biolog
complement
current
antiiav
arsen
influenza
persist
threat
human
health
continu
requir
updat
antiinfluenza
strategi
initi
observ
differ
endoplasm
reticulum
er
respons
host
season
highli
pathogen
avian
influenza
hpai
infect
identifi
altern
antivir
role
tauroursodeoxychol
acid
tudca
clinic
avail
er
stress
inhibitor
vitro
vivo
rather
modul
er
stress
host
cell
tudca
abolish
proton
conduct
viral
disrupt
oligomer
state
induc
ineffici
viral
infect
also
show
penetr
cell
whose
intracellular
uptak
depend
proton
channel
activ
effect
observ
tudca
inhibitor
amantadin
identif
applic
tudca
inhibitor
proton
channel
expand
understand
iav
biolog
complement
current
antiiav
arsen
scienc
china
press
publish
elsevi
bv
scienc
china
press
right
reserv
major
human
pathogen
influenza
virus
iav
continu
induc
annual
outbreak
irregular
epidem
highli
pathogen
avian
influenza
hpai
one
plausibl
candid
caus
deadli
flu
outbreak
though
basi
increment
virul
larg
unclear
clinic
data
suggest
high
viral
load
result
cytokin
storm
primari
instig
factor
therefor
identifi
therapi
target
viral
element
involv
differ
step
iav
life
cycl
remain
public
health
prioriti
life
cycl
envelop
iav
initi
receptormedi
endocytosi
inhibit
present
ideal
approach
restrict
iav
replic
spread
dynam
entri
iav
start
bind
haemagglutinin
ha
sialic
acid
follow
two
phcontrol
event
optim
acid
milieu
late
endosom
trigger
conform
alter
ha
fuse
iav
host
endosom
membran
prior
fusion
acid
activ
ion
channel
occur
earli
endosom
facilit
iav
uncoat
thu
inhibit
ha
constitut
primari
mechan
suppress
iav
entri
though
inhibitor
amantadin
rimantadin
block
iav
entri
emerg
adamantaneresist
associ
advers
effect
temper
clinic
applic
homotetram
monom
consist
amino
acid
includ
ectodomain
transmembran
tm
region
cytosol
tail
contain
amphipath
ahelix
ah
proton
conduct
may
involv
interact
proton
tm
acid
ph
respons
adamantanebas
sensit
oligomer
base
assess
either
tetramer
tm
peptid
dimer
fulllength
particularli
necessari
entir
channel
function
tm
suffici
form
tetramer
unstabl
unless
ah
present
though
structur
conform
function
remain
unclear
deform
oligomer
pave
way
develop
antiiav
drug
bile
acid
ba
amphipath
molecul
compos
hydrophob
backbon
hydrophil
hydroxyl
group
ba
usual
conjug
taurin
increas
hydrophil
babas
medic
evolv
hydrophob
chenodeoxychol
acid
cdca
taurineconjug
tcdca
hydrophil
ursodeoxychol
acid
udca
taurineconjug
tudca
later
strategi
current
fdaapprov
treatment
human
liver
disord
sinc
ba
reduc
intracellular
protein
aggreg
chaperon
udca
tudca
consid
chemic
chaperon
recent
tudca
implic
therapi
hepat
b
viru
infect
tudca
also
inhibit
iav
replic
suppress
inositolrequir
enzym
branch
unfold
protein
respons
upr
conserv
molecular
network
orchestr
er
patholog
current
studi
observ
distinct
er
respons
season
highli
pathogen
infect
lung
epithelium
though
lack
typic
upr
signal
er
stress
inhibitor
tudca
suffici
prevent
lung
injuri
upr
independ
manner
result
show
disrupt
proton
channel
may
account
tudca
inhibit
iav
infect
human
lung
adenocarcinoma
cell
line
obtain
atcc
madindarbi
canin
kidney
mdck
human
embryon
kidney
cell
purchas
cell
resourc
centr
peke
union
medic
colleg
beij
china
detail
given
supplement
experiment
procedur
avian
influenza
viru
season
influenza
viru
anew
use
studi
obtain
inocul
stock
viru
old
specificpathogenfre
spf
embryon
chicken
egg
harvest
allanto
fluid
af
egg
anim
infect
spfhous
mice
old
male
g
vital
river
beij
china
use
infect
lung
injuri
induc
intratrach
inject
live
iav
titr
tcid
tcid
ident
volum
af
vehicl
control
bodi
weight
surviv
rate
record
everi
day
intratrach
challeng
either
af
iav
tudca
mgkg
intratrach
administr
mice
h
iav
exposur
h
iav
inject
determin
prophylact
therapeut
effect
respect
dose
tudca
vivo
test
chosen
previou
studi
histolog
assess
mous
lung
tissu
measur
mous
lung
wetdri
ratio
perform
day
post
infect
lung
injuri
score
fulfil
describ
detail
given
supplement
experiment
procedur
applic
institut
andor
nation
guidelin
care
use
anim
follow
ivlp
obtain
transfect
cell
plasmid
encod
iav
element
ivlpbas
proton
channel
activ
measur
modifi
previous
publish
protocol
detail
given
supplement
experiment
procedur
quantif
intracellular
ivlp
determin
accuri
flow
cytomet
becton
dickinson
bd
franklin
lake
nj
usa
analyz
use
flowjo
softwar
treestar
ashland
usa
correspond
antibodi
detail
supplement
experiment
procedur
confoc
imag
includ
acid
bypass
test
acquir
use
olympu
confoc
microscop
olympu
tokyo
japan
quantif
signal
perform
olympu
fluoview
olympu
neg
stain
ivlp
observ
infect
cell
perform
transmiss
electron
microscop
jem
jeol
tokyo
japan
detail
given
supplement
experiment
procedur
data
shown
mean
sem
analyz
accord
least
independ
experi
twogroup
comparison
analyz
student
ttest
statist
test
multipl
group
perform
anova
follow
turkey
posttest
ibm
spss
graphpad
prism
san
diego
ca
usa
p
consid
statist
signific
previou
studi
show
tudca
constrain
season
iavinduc
upr
lung
epithelium
consist
observ
increas
bip
signal
upr
cell
infect
season
new
iav
fig
onlin
upr
activ
occur
parallel
hyperplasia
smooth
er
becam
strike
h
post
infect
fig
howev
upr
respons
pathway
absent
hpai
host
fig
onlin
includ
branch
fig
onlin
though
lack
typic
upr
signatur
remark
er
swell
detect
h
infect
fig
result
confirm
er
involv
iav
life
cycl
suggest
differ
er
respons
season
highli
pathogen
iav
infect
contrast
previou
report
upr
activ
mediat
pandem
iavinduc
acut
lung
injuri
ali
absenc
upr
highli
pathogen
cell
studi
suggest
altern
underli
mechan
light
sever
er
swell
induc
h
infect
explor
potenti
clinic
avail
er
stress
inhibitor
tudca
strategi
investig
action
er
chaperon
first
test
effect
tudca
cell
ad
h
infect
tudca
restor
cell
viabil
h
exposur
fig
nearli
undetect
viral
load
fig
notabl
effect
tudca
achiev
rel
high
dose
much
greater
use
reliev
er
stress
view
good
toler
appar
benefit
high
dose
tudca
lethal
iav
infect
fig
onlin
util
mmol
l
vitro
studi
due
lack
upr
tudca
impact
upr
marker
cell
though
cell
could
possess
tight
associ
tudca
fig
b
onlin
shown
previous
contrast
fail
rescu
cell
death
fig
f
onlin
support
uprindepend
antivir
action
tudca
moreov
protect
host
infect
unsuccess
tudca
ad
h
post
challeng
compar
prophylact
intervent
h
therapeut
treatment
within
h
infect
fig
h
critic
time
point
correspond
end
ha
fusion
start
viral
genom
transport
result
suggest
iav
entri
target
tudca
examin
antientri
role
tudca
quantifi
intern
iav
h
post
infect
fig
infect
cell
np
posit
stain
total
cell
area
h
infect
respect
tudca
reduc
np
signal
h
post
infect
note
blockag
iav
entri
tudca
exclus
found
similar
suppress
iav
entri
cell
infect
fig
onlin
altogeth
result
provid
evid
tudca
inhibit
iav
entri
mechan
iav
entri
reflect
interplay
iav
host
endocyt
machineri
clarifi
step
tudca
play
role
permut
tudca
treatment
four
tactic
base
tudca
administ
host
name
either
concomit
iav
infect
fig
onlin
intriguingli
even
cell
preexpos
long
tudca
appli
iav
infect
tudca
inhibit
iav
entri
compar
condit
tudca
ad
infect
meanwhil
presenc
tudca
infect
critic
remov
tudca
infect
even
h
pretreat
host
fail
prevent
viral
infect
effect
similar
nontudcatr
cell
result
suggest
antiiav
effect
tudca
unlik
reli
prime
host
cell
verifi
point
test
dynam
host
cell
endocytosi
use
virusfre
fluorescencelabel
dextran
fig
result
show
inhibit
dextran
uptak
tudca
min
dextran
load
indic
tudca
affect
host
endocytosi
addit
tudca
bile
acid
may
sequest
cholesterol
cellular
membran
lead
attenu
viral
entri
found
decreas
intern
cell
preincub
cholesteroldeplet
methylbcyclodextrin
mbcd
fig
onlin
consist
cell
altogeth
data
indic
tudca
may
target
iav
instead
host
ha
mediat
receptorbind
acidcontrol
fusion
iav
entri
test
effect
tudca
ha
use
acid
bypass
assay
briefli
acid
bypass
mimic
acid
environ
late
endosom
extracellular
compart
deceiv
viral
ha
expos
fusionpeptid
without
alloc
late
endosom
respons
acid
preattach
iav
immedi
fuse
plasma
membran
shown
fig
inhibit
tudca
iav
intern
complet
abolish
acid
bypass
appli
suggest
tudca
interfer
receptorbind
fusion
ha
gain
deeper
insight
individu
element
iav
envelop
util
influenza
viruslik
particl
ivlp
sinc
essenti
effici
ivlp
assembl
creat
ivlp
contain
ha
na
ha
na
fig
b
onlin
determin
entri
ivlp
cell
fig
onlin
result
show
tudca
minor
effect
uptak
howev
tudca
interrupt
intern
even
absenc
fusion
protein
ha
fig
gain
insight
mechan
tudca
suppress
cellpenetr
test
whether
intern
via
endocyt
pathway
employ
bafilomycin
chloroquin
cq
observ
elev
signal
cell
fig
onlin
pattern
indic
defici
degrad
engulf
suggest
endocytosi
mechan
entri
cell
clarifi
compon
determin
cellpenetr
util
mammaliancel
deriv
protein
treat
cell
cellbas
experi
detect
endocytos
cell
howev
iav
could
clearli
detect
attenu
tudca
fig
onlin
togeth
inhibit
uptak
inhibitor
amantadin
fig
like
entri
moreov
coincub
tudca
reveal
dimer
tetram
especi
tetram
lost
tudca
present
ha
na
remain
unalt
three
ivlp
creat
fig
verifi
band
oligom
specif
antibodi
fig
onlin
confirm
disrupt
oligom
tudca
coincub
tudca
either
authent
iav
fig
correspond
strain
fig
onlin
result
show
tudca
impair
tetram
iav
without
obviou
impact
ha
authent
iav
collect
data
provid
critic
evid
effect
tudca
associ
sinc
oligomer
stage
may
affect
channel
activ
examin
proton
conduct
challeng
fig
ivlp
incorpor
gag
fig
onlin
acid
buffer
result
membran
depolar
indic
activ
respons
tudca
inject
acidstimul
proton
transloc
larg
abolish
fig
onlin
indic
function
requir
oligomer
howev
amantadin
rimantadin
treatment
augment
tetramer
fig
onlin
suggest
dissimilar
mechan
action
tudca
furthermor
use
tem
observ
form
liposomelik
structur
distinct
protein
alon
consist
endocytosi
protein
protein
dramat
disrupt
tudca
addit
fig
confirm
atom
forc
microscopi
afm
fig
onlin
final
assess
whether
tudca
potenti
antiiav
therapi
test
effect
tudca
prophylact
therapeut
approach
administ
prophylact
tudca
salin
intraperiton
mice
h
intratrach
challeng
iav
similar
vitro
data
tudca
increas
surviv
rate
mice
without
detect
side
effect
fig
reduc
bodi
weight
infect
mice
improv
tudcatr
subject
fig
lung
injuri
score
base
h
e
stain
fig
indic
reduct
lung
impair
tudcatr
mice
fig
pulmonari
edema
infect
mice
dramat
recov
tudcatr
group
fig
result
indic
tudca
highli
effect
prophylact
treatment
iavinduc
diseas
convers
tudca
treatment
began
h
exposur
surviv
rate
bodi
weight
tudcatr
group
indistinguish
nontreat
group
fig
b
onlin
vivo
observ
confirm
tudca
target
intern
rather
replic
iav
role
er
iav
infect
welldocu
activ
upr
uniqu
featur
er
iavinfect
cell
though
mechan
iav
induc
er
stress
attribut
accumul
iav
protein
er
lumen
iav
replic
chang
er
morpholog
h
post
exposur
indic
interact
er
iav
besid
assembl
fold
newli
synthes
protein
er
intracellular
bank
ca
also
regul
cytosol
ca
inde
iav
infect
induc
cytosol
ca
oscil
host
cell
requir
effici
iav
intern
yet
detail
behind
er
pathophysiolog
iav
entri
remain
mostli
unclear
open
interest
question
whether
upr
activ
induc
detriment
benefici
host
respons
follow
iav
infect
whether
typic
er
signal
serv
indic
viral
virul
current
studi
gener
seri
ivlp
among
unexpect
first
form
liposomelik
structur
measur
proton
channel
activ
second
penetr
freeli
cell
probabl
endocyt
pathway
third
penetr
potenti
may
reli
like
endow
cellpenetr
compet
first
identif
protein
move
across
cellular
membran
group
protein
similar
featur
classifi
cellpenetr
peptid
cpp
one
class
cpp
identifi
compris
high
degre
amphipath
ah
common
structur
motif
ah
hydrophil
hydrophob
amino
acid
usual
group
separ
face
helix
highli
hydrophob
patch
one
face
cation
patch
face
penetr
cpp
contain
ah
mainli
due
amphipath
ah
regard
exist
ah
cterminu
report
sever
group
put
function
involv
viral
bud
scission
express
host
cell
ah
arrang
parallel
membran
partial
penetr
hydrophob
face
mediat
membran
deform
regard
plausibl
ah
util
similar
mechan
trigger
iav
entri
induc
membran
curvatur
howev
due
interior
iav
like
ah
reinforc
contact
viral
envelop
host
membran
protrud
viral
envelop
implic
cpp
far
fulli
defin
addit
work
requir
understand
whether
cpp
properti
natur
iav
entri
besid
cellpenetr
ah
posit
charg
could
attract
neg
charg
ba
ba
facial
amphiphil
adopt
almost
flat
conform
rigid
steroid
backbon
parallel
interfac
allow
contact
hydroxyl
group
aqueou
environ
typic
conjug
head
group
ba
abl
captur
cation
speci
tem
afm
data
fig
g
onlin
suggest
tudca
may
form
complex
inherit
flat
conform
ba
complex
may
compos
hydrophob
interfac
ba
parallel
hydrophil
contact
via
electrostat
forc
posit
charg
ah
neg
charg
tudca
thu
tudca
reorgan
protein
deform
liposom
construct
shown
string
membran
debri
bind
featur
ba
usual
appear
millimolar
concentr
may
explain
high
dose
tudca
requir
studi
taken
togeth
identifi
altern
antivir
role
tudca
rather
modul
upr
host
cell
disrupt
viral
proton
channel
may
mediat
antiiav
effect
tudca
applic
class
inhibitor
unravel
previous
unidentifi
import
mechan
expand
understand
iav
biolog
tudca
clinic
avail
medic
liver
disord
current
clinic
evalu
metabol
syndrom
antivir
potenti
repurpos
exist
pharmacolog
treatment
may
complement
current
antiiav
arsen
ningyi
jin
academician
chines
academi
engin
professor
institut
militari
veterinari
medicin
academi
militari
medicin
academi
militari
scienc
dr
jin
research
interest
includ
isol
identif
characterist
viru
relat
mechan
infect
pathogenesi
viru
viral
etiolog
epidemiolog
law
distribut
harm
viral
diseas
earli
warn
scientif
prevent
control
viral
diseas
viru
detect
technolog
earli
diagnosi
rapid
detect
viru
diseas
vaccin
prepar
technolog
platform
genet
engin
vaccin
drug
chengyu
jiang
professor
execut
vice
dean
school
basic
medicin
peke
union
medic
colleg
chines
academi
medic
scienc
research
elucid
molecular
pathogenesi
acut
respiratori
distress
syndrom
induc
rna
virus
sarscov
avian
swine
influenza
ebola
dr
jiang
propos
number
repurpos
drug
elucid
diseas
molecular
target
